Table 2.
Secondary outcome measures of disease activity (month 6 randomization and month 12)
| ETN (N=98) | ETN+MTX (N=107) | |||||
|---|---|---|---|---|---|---|
| Mean (CI) at month 6 | Mean (CI) at month 12 | Mean Δ (CI) month 6 to 12 | Mean (CI) at month 6 | Mean (CI) at month 12 | Mean Δ (CI) month 6 to 12 | |
| HAQ (0–3) | 0.8 (0.7 to 0.9) | 1.0 (0.8 to 1.1) | 0.2 (0.1 to 0.2) | 1.0 (0.9 to 1.1) | 1.0 (0.9 to 1.2) | 0.03 (−0.06 to 0.12) |
| PtGA (0–100) | 28.3 (23.6 to 33.0) | 35.1 (30.0 to 40.2) | 6.8 (2.3 to 11.3) | 29.2 (24.6 to 33.7) | 33.2 (28.1 to 38.3) | 4.0 (−0.6 to 8.7) |
| PGA (0–100) | 17.7 (14.4 to 21.0) | 28.6 (23.5 to 33.7) | 10.9 (5.8 to 15.9) | 17.3 (14.2 to 20.4) | 22.5 (17.9 to 27.0) | 4.7 (0.8 to 8.6) |
| Pain VAS (0–100) | 32.5 (27.4 to 37.6) | 39.8 (34.4 to 45.1) | 7.3 (3.0 to 11.5) | 34.3 (29.0 to 39.6) | 37.1 (31.6 to 42.5) | 2.1 (−2.4 to 6.7) |
DAS28 is calculated with erythrocyte sedimentation rate; DAS, disease activity score; ETN, etanercept; HAQ, Health Assessment Questionnaire; MTX, methotrexate; PGA, Physician Global Assessment; PtGA, Patient Global Assessment; VAS, visual analog scale.